Clinical Trial Update: A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA [Phase 3]

View source ↗

Summary

A Phase III trial investigating post-radiation detectable plasma EBV DNA in nasopharyngeal carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: TERMINATED